News & Updates

Increasing low potassium levels improves clinical outcomes in patients with cardiovascular disease (CVD) and a high risk for ventricular arrhythmias, as shown in the POTCAST trial presented at ESC 2025.

Adding the cardiac glycoside digitoxin to guideline-directed medical therapy (GDMT) improves clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF), as shown in the DIGIT-HF trial, which took over 10 years to complete due to funding constraints.

Findings from the phase III ROCKET-SHUTTLE trial support the treatment potential of rocatinlimab for atopic dermatitis (AD).

Women with refractory overactive bladder (OAB) may improve their symptoms by using either intradetrusor onabotulinumtoxinA or combined pharmacotherapy with solifenacin and mirabegron, suggests a study.